MP
$425,000 – $600,000
Listed on Menlo Ventures Portfolio’s own careers site. You apply with them directly — we never stand between you and the employer.
What this role is
Anthropic seeks a corporate development leader to identify and execute transactions—acquisitions, investments, and partnerships—with AI-native life sciences companies that are applying frontier AI to drug discovery, clinical development, and related workflows. This role suits someone with deep biotech domain expertise, technical AI fluency, and a track record closing complex deals who can assess both the science and the business behind AI applications in regulated healthcare settings.
Our summary, not Menlo Ventures Portfolio’s wording. The full posting is on their site.
What they ask for
Required
- Led complex M&A, investment, or partnership transactions from sourcing through close
- Understand drug development lifecycle from discovery through commercialization
- Technical fluency in AI and software from engineering, product management, science, or technology investing
- Strong analytical and financial modeling skills
- Ability to engage credibly with scientists, engineers, executives, and regulators
- Comfortable in fast-paced, ambiguous environments
- Clear written and spoken communication with influence across levels
- Deep interest in AI safety and Anthropic's mission
Nice to have
- 8–12 years in corporate development, investment banking, or investing with at least 5 years in life sciences, biotech, or healthcare technology
- Advanced degree in life sciences (PhD, MD, PharmD) or MBA
- Experience at pharmaceutical company, biotech, CRO, or life sciences software company
- Experience with AI/ML applied to biology, chemistry, or clinical operations
- Established network among life sciences founders, healthcare VCs, and pharma business development leaders
- Diligence or integration experience with GxP, HIPAA, or similar regulatory regimes
- Led post-merger integration or built a new business unit
- Experience with cross-border transactions in US, EU, and UK life sciences markets